An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome.

ABSTRACT:

Background

Minocycline, a member of the tetracycline family, has a low risk of adverse effects and an ability to improve behavioral performance in humans with cognitive disruption. We performed a single-arm open-label trial in which 25 children diagnosed with Angelman syndrome (AS) were administered minocycline to assess the safety and tolerability of minocycline in this patient population and determine the drug's effect on the cognitive and behavioral manifestations of the disorder.

Methods

Participants, age 4-12 years old, were randomly selected from a pool of previously screened children for participation in this study. Each child received 3 milligrams of minocycline per kilogram of body weight per day for 8 weeks. Participants were assessed during 3 study visits: baselin

SUBMITTER: Grieco JC 

PROVIDER: S-EPMC4276108 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature